Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Retroviruses

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Combined Effects of Drugs: Antagonism

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.

The Journal of antimicrobial chemotherapy·2024

Same author

Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.

The Journal of antimicrobial chemotherapy·2023

Same author

Pharmacokinetics, the Immunological Impact, and the Effect on HIV <i>Ex-Vivo</i> Infectivity of Maraviroc, Raltegravir, and Lopinavir in Men Who Have Sex with Men Using Postexposure Prophylaxis.

AIDS research and human retroviruses·2022

Same author

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2022

Same author

Early Enteral Nutrition and Gastrointestinal Complications in Pediatric Patients on Extracorporeal Membrane Oxygenation.

Journal of pediatric gastroenterology and nutrition·2021

Same author

Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.

The lancet. HIV·2021

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

[Secondary effects associated with raltegravir].

José M Gatell¹, Laura Zamora

¹Servicio de Infecciones, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, España. gatell0@attglobal.net

Enfermedades Infecciosas Y Microbiologia Clinica

|July 3, 2009

Summary

Raltegravir, the first integrase inhibitor for HIV, shows a positive risk-benefit profile. Clinical trials confirm its safety and efficacy, with mild side effects and a better lipid profile than efavirenz.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells

An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells

Published on: August 15, 2012

Related Experiment Videos

Last Updated: Jun 22, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells

An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells

Published on: August 15, 2012

Area of Science:

Virology
Pharmacology
Immunology

Background:

Human Immunodeficiency Virus (HIV) infection requires novel therapeutic strategies.
Integrase inhibitors represent a new class of antiretroviral drugs targeting viral replication.
Raltegravir is the first approved integrase inhibitor for clinical use.

Purpose of the Study:

To evaluate the safety and efficacy of raltegravir as an HIV therapeutic.
To assess the toxicological profile of raltegravir in preclinical and clinical studies.
To compare the safety and lipid profile of raltegravir against existing antiretroviral drugs.

Main Methods:

Review of preclinical safety studies including genotoxicity, carcinogenicity, and reproductive toxicology.
Analysis of adverse events reported during clinical trials of raltegravir.
Comparison of raltegravir's safety and lipid profile with efavirenz.

Main Results:

Preclinical studies showed no significant toxicity at therapeutic doses.
Clinical trials demonstrated a favorable safety profile with mild-to-moderate adverse effects (diarrhea, nausea, headache).
Raltegravir exhibited a superior lipid profile compared to efavirenz.

Conclusions:

Raltegravir demonstrates a positive risk-benefit ratio for HIV treatment.
The drug's targeted mechanism on viral integrase suggests low host cell toxicity.
Raltegravir is a safe and effective option for managing HIV infection.